Alector

Alector's platform is built on the observation that some individuals carry natural genetic variations that increase or decrease their risk of developing neurodegenerative diseases like Alzheimer's and frontotemporal dementia. The firm identifies these protective or risk-conferring genes and develops monoclonal antibodies to either enhance protective functions or block damaging ones. The central thesis is that restoring the brain's immune function — rather than exclusively clearing protein aggregates — can alter the course of disease.

Alector and AbbVie entered a global co-development and co-commercialization partnership in 2017 focused on novel Alzheimer's disease targets (per public record, 2017). The collaboration expanded in 2023 to include an additional discovery-stage program. Under the partnership, Alector leads discovery through a certain clinical stage, after which costs and profits are shared between the two companies.

Latozinemab, a progranulin-elevating antibody for frontotemporal dementia patients with GRN gene mutations, is in a pivotal Phase 3 trial called INFRONT-3 (per the firm, 2024). AL002, which targets TREM2 activity in early Alzheimer's disease, completed enrollment in a Phase 2 study. Both programs represent the firm's core immuno-neurology thesis and are the primary value drivers ahead of their respective clinical data readouts.

Alector was co-founded in 2013 by Arnon Rosenthal, Asa Abeliovich, and Tillman Gerngross. Rosenthal serves as CEO and was previously a venture partner at OrbiMed. Abeliovich, a neurologist from Columbia University, contributed the human-genetics screening logic central to the firm's pipeline. Gerngross, an engineer at Dartmouth College, founded the antibody discovery company Adimab, which provides the molecular engineering backbone for Alector's biologic drugs.

Alector does not directly target amyloid-beta plaques or tau tangles. Instead, the firm focuses on microglia and other immune cells in the brain, aiming to restore their normal housekeeping and protective functions. This strategy is designed to address the underlying neuroinflammation and dysfunction that contributes to multiple types of neurodegeneration, not just amyloid-related pathology.

In March 2024, Alector announced a restructuring that reduced its workforce by approximately 17% (per the firm, March 2024). The move was designed to reduce operating expenses and extend the company's cash runway, with a sharpened focus on advancing latozinemab through its pivotal Phase 3 trial in frontotemporal dementia. The restructuring reflected the biotech sector's broader emphasis on prioritizing late-stage clinical assets amid a constrained financing environment.

No. While Alzheimer's disease is a major focus, Alector's lead program targets frontotemporal dementia with a specific progranulin gene mutation. The firm's genetic-discovery platform is designed to identify targets relevant across multiple neurodegenerative diseases, and its pipeline includes programs aimed at genetically defined subpopulations of Parkinson's disease and other dementias.